MELAS syndrome

Oct 07, 2019

Mitochondrial Disease Therapies Market, 2019-2030

Nov 15, 2018

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders

Aug 28, 2018

NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia

Jun 18, 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics

Apr 26, 2018

Mode of Action of the Mitochondrial Clinical-stage Drug Candidate Kh176: Two Birds, One Stone

Apr 20, 2018

NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference

Apr 18, 2018

NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

Jan 29, 2018

NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project

Dec 11, 2017

NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333

Nov 30, 2017

NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone

Nov 16, 2017

Khondrion Will Present First Results of KHENERGY Study

Nov 08, 2017

New Patents Granted for Khondrion's Mitochondrial Disease Lead Compound KH176

Jun 27, 2017

NeuroVive and Yungjin Pharm Start Clinical Development in Genetic Mitochondrial Disease